- Home
- GLTO vs BOF Comparison
GLTO vs BOF Comparison
Compare GLTO & BOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- BOF
- Stock Information
- Founded
- GLTO 2011
- BOF 2017
- Country
- GLTO Denmark
- BOF United States
- Employees
- GLTO N/A
- BOF N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- BOF Packaged Foods
- Sector
- GLTO Health Care
- BOF Consumer Staples
- Exchange
- GLTO Nasdaq
- BOF Nasdaq
- Market Cap
- GLTO 23.7M
- BOF 27.6M
- IPO Year
- GLTO 2020
- BOF 2023
- Fundamental
- Price
- GLTO $5.72
- BOF $3.05
- Analyst Decision
- GLTO
- BOF
- Analyst Count
- GLTO 0
- BOF 0
- Target Price
- GLTO N/A
- BOF N/A
- AVG Volume (30 Days)
- GLTO 767.1K
- BOF 3.7M
- Earning Date
- GLTO 11-04-2025
- BOF 11-13-2025
- Dividend Yield
- GLTO N/A
- BOF N/A
- EPS Growth
- GLTO N/A
- BOF N/A
- EPS
- GLTO N/A
- BOF N/A
- Revenue
- GLTO N/A
- BOF $10,179,595.00
- Revenue This Year
- GLTO N/A
- BOF N/A
- Revenue Next Year
- GLTO N/A
- BOF N/A
- P/E Ratio
- GLTO N/A
- BOF N/A
- Revenue Growth
- GLTO N/A
- BOF 95.18
- 52 Week Low
- GLTO $2.01
- BOF $1.52
- 52 Week High
- GLTO $31.70
- BOF $3.37
- Technical
- Relative Strength Index (RSI)
- GLTO 42.06
- BOF 63.40
- Support Level
- GLTO $7.02
- BOF $2.95
- Resistance Level
- GLTO $7.64
- BOF $3.29
- Average True Range (ATR)
- GLTO 0.58
- BOF 0.32
- MACD
- GLTO -0.55
- BOF 0.04
- Stochastic Oscillator
- GLTO 0.25
- BOF 78.24
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About BOF BranchOut Food Inc.
Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders. Its products are currently manufactured for the company by contract manufacturers based in South America and North America that produce dehydrated fruit and vegetable products for the company using a new proprietary dehydration technology that it licenses from a third party. The Company's customers are located throughout the United States. Its current primary products are BranchOut Snacks, BranchOut Powders, and BranchOut Industrial Ingredients.